PeptiDreamPeptiDream Inc.4587東証プライム医薬品FY ending Dec 2024, consolidated, IFRS
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Dec 2021 | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 |
|---|---|---|---|---|---|---|
| Drug Discovery and Development Business | N/A | — | — | — | — | 31,31366.9% |
| Radiopharmaceuticals Business | N/A | — | — | — | — | 15,3631.6% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第20期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第19期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第16期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第15期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 41 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.